Toxic Keratopathy Associated with Suramin Therapy

Publisher Website
Google Scholar
Abstract
To the Editor: Suramin, an inhibitor of reverse transcriptase of HTLV-III,1 has been used for many years in the treatment of African trypanosomiasis and onchocerciasis. It now is being used in clinical trials to evaluate its efficacy in patients with AIDS. We have observed a toxic keratopathy possibly due to suramin in these patients.Five patients with AIDS who had no visual symptoms and who were treated with suramin at our institution underwent ophthalmologic evaluations including slit-lamp examinations. All received 500 mg to 1 g of intravenous suramin weekly after an initial dose of 200 mg. Two patients had been . . .